ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Leukemia
Cancer
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Portland, OR, USA:

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

AbbVie
AbbVie

Portland, Oregon, United States and 40 other locations

of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, i...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Cyclophosphamide

Phase 3

Gilead Sciences
Gilead Sciences

Portland, Oregon, United States and 59 other locations

of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Biological: Arlocabtagene Autoleucel (BMS-986393)

Phase 2

Juno Therapeutics

Portland, Oregon, United States and 51 other locations

antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Portland, Oregon, United States and 18 other locations

A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Ani...

Enrolling
Multiple Myeloma
Biological: anitocabtagene-autoleucel

Phase 2

Gilead Sciences
Gilead Sciences

Portland, Oregon, United States and 19 other locations

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Portland, Oregon, United States and 285 other locations

the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Teclistamab

Phase 1, Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Portland, Oregon, United States and 39 other locations

receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 1...

Enrolling
Multiple Myeloma
Drug: Dara-VRd induction
Drug: Dara-VRd intensification, Dara-R maintenance

Phase 2

The University of Alabama at Birmingham
The University of Alabama at Birmingham

Portland, Oregon, United States and 9 other locations

Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of ...

Active, not recruiting
Multiple Myeloma of Bone
Multiple Myeloma in Relapse
Drug: MK-4002

Phase 1

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Portland, Oregon, United States and 12 other locations

find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any sign...

Enrolling
Multiple Myeloma
Drug: Linvoseltamab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Portland, Oregon, United States and 41 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems